Skip to content
Facebook page opens in new windowLinkedin page opens in new windowTwitter page opens in new window
Guardian Pharmacy Services
Long-Term Care Pharmacy
Guardian Pharmacy Services
  • Our Story
    • About Us
    • Core Values
    • History
    • Leadership
  • Our Services
    • Resident & Family Resources
      • Resident & Family Services
      • LTC Pharmacy Services
      • Medication Safety in Assisted Living
      • Questions About Medicare
    • Provider Services
    • GuardianShield
    • eMAR / EHR Partners
    • GuardianNote Login
    • GuardianHub Login
  • Who We Serve
    • Assisted Living & Memory Care
    • Post-Acute & Long-Term Care
    • Mental & Behavioral Health
    • Intellectual & Developmental Disabilities
    • Hospice Care
    • PACE Programs
    • Other Care Organizations
  • Locations
  • News & Resources
    • News & Events
    • Blog
    • Resources
    • Media Contact
  • Investors
Contact Us
  • Home
  • Our Story
    • About Us
    • Core Values
    • History
    • Leadership
  • Our Services
    • Resident & Family Resources
      • Resident & Family Services
      • LTC Pharmacy Services
      • Medication Safety in Assisted Living
      • Medicare Options
    • Provider Services
    • GuardianShield
    • eMAR / EHR Partners
    • GuardianNote Login
    • GuardianHub Login
  • Who We Serve
    • Assisted Living & Memory Care
    • Post-Acute & Long-Term Care
    • Mental & Behavioral Health
    • Intellectual & Developmental Disabilities
    • Hospice Care
    • PACE Programs
    • Other Care Organizations
  • News & Resources
    • News & Events
    • Blog
    • Resources
    • Media Contact
  • Investors
  • Locations
  • Careers
  • Contact

Monthly Archives: February 2015

You are here:
  1. Home
  2. 2015
  3. February

Guardian 46th in Top 100 Private Companies

NewsBy February 24, 2015

The company received its highest ranking in six years.

Guardian Atlanta featured in McKnight’s

NewsBy February 12, 2015

Will the reclassification of hydrocodone combination products to a more restrictive level pose potential complications for providers?

Go to Top